journal
MENU ▼
Read by QxMD icon Read
search

Journal of the National Comprehensive Cancer Network: JNCCN

journal
https://www.readbyqxmd.com/read/30323095/toward-a-personalized-approach-in-the-treatment-of-salivary-ductal-carcinoma
#1
Frederick D Tsai, Robert I Haddad
No abstract text is available yet for this article.
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30323094/immune-checkpoint-inhibitor-therapy-in-breast-cancer
#2
REVIEW
Cesar A Santa-Maria, Rita Nanda
Initial studies investigating single-agent activity of immune checkpoint inhibitors (ICIs) serve as proof of principle that harnessing the immune system can have anticancer activity in a variety of human malignancies. Although breast cancer was historically believed to be immunogenically silent, early studies indicate overall response rates with ICIs are similar to those observed with many other solid malignancies. Overall response rates in advanced breast cancer are low, but the responses are remarkably durable...
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30323093/preventive-health-in-cancer-survivors-what-should-we-be-recommending
#3
REVIEW
Linda S Overholser, Carlin Callaway
Individuals with a history of cancer, often referred to as cancer survivors , may experience late and long-term effects of their treatment. Because these individuals live longer in the survivorship phase, some of these late effects may also be considered risk factors for other chronic conditions. With cancer and cardiovascular disease now the top 2 leading causes of death in the United States and with common risk factors for both, as well as the morbidity that can occur after cancer treatment, preventive health is becoming an important issue in cancer survivorship care...
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30323092/survivorship-version-2-2018-nccn-clinical-practice-guidelines-in-oncology
#4
Crystal S Denlinger, Tara Sanft, K Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Robin M Lally, Terry S Langbaum, Allison L McDonough, Michelle Melisko, Jose G Montoya, Kathi Mooney, Javid J Moslehi, Tracey O'Connor, Linda Overholser, Electra D Paskett, Jeffrey Peppercorn, William Pirl, M Alma Rodriguez, Kathryn J Ruddy, Paula Silverman, Sophia Smith, Karen L Syrjala, Amye Tevaarwerk, Susan G Urba, Mark T Wakabayashi, Phyllis Zee, Nicole R McMillian, Deborah A Freedman-Cass
The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for common physical and psychosocial consequences of cancer and cancer treatment to help healthcare professionals who work with survivors of adult-onset cancer in the posttreatment period. This portion of the guidelines describes recommendations regarding the management of anthracycline-induced cardiotoxicity and lymphedema. In addition, recommendations regarding immunizations and the prevention of infections in cancer survivors are included...
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30323091/tumor-board-conferences-for-multidisciplinary-skin-cancer-management-a-survey-of-us-cancer-centers
#5
Shoko Mori, Cristian Navarrete-Dechent, Tatyana A Petukhova, Erica H Lee, Anthony M Rossi, Michael A Postow, Lara A Dunn, Benjamin R Roman, Vivian T Yin, Daniel G Coit, Travis J Hollmann, Klaus J Busam, Kishwer S Nehal, Christopher A Barker
Background: Tumor board conferences (TBCs) are used by oncologic specialists to review patient cases, exchange knowledge, and discuss options for cancer management. These multidisciplinary meetings are often a cornerstone of treatment at leading cancer centers and are required for accreditation by certain groups, such as the American College of Surgeons' Commission on Cancer. Little is known regarding skin cancer TBCs. The objective of this study was to characterize the structure, function, and impact of existing skin cancer TBCs in the United States...
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30323090/a-study-of-novel-febrile-neutropenia-risk-factors-related-to-bone-marrow-or-immune-suppression-barrier-function-and-bacterial-flora
#6
Leila Family, Yanli Li, Lie Hong Chen, John H Page, Zandra K Klippel, Chun Chao
Background: Previously identified patient-level risk factors for chemotherapy-induced febrile neutropenia (FN) indicate several potential underlying pathogenic mechanisms, including bone marrow suppression, impaired neutrophil function, or disturbances of barrier function. This study evaluated whether additional clinical characteristics related to these pathogenic mechanisms were risk factors for FN. Patients and Methods: The study population included patients diagnosed with non-Hodgkin's lymphoma or breast, lung, colorectal, ovarian, or gastric cancer between 2000 and 2009 at Kaiser Permanente Southern California and treated with myelosuppressive chemotherapy...
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30323089/systemic-therapy-for-combined-hepatocellular-cholangiocarcinoma-a-single-institution-experience
#7
Nikolaos A Trikalinos, Amy Zhou, Maria B Majella Doyle, Kathryn J Fowler, Ashley Morton, Neeta Vachharajani, Manik Amin, Jesse W Keller, William C Chapman, Elizabeth M Brunt, Benjamin R Tan
Background: Combined hepatocellular-cholangiocarcinoma tumors (cHCC-CCA) are a heterogeneous group of rare malignancies that have no established optimal treatment. Patients and Methods: We identified patients with cHCC-CCA treated at a tertiary center and retrospectively examined their histology, interventions, and outcomes. We calculated disease control rate (DCR), disease progression, overall survival, and progression-free survival (PFS) between treatment subgroups. Results: A total of 123 patients were evaluable...
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30323088/a-routine-laboratory-data-based-model-for-predicting-recurrence-after-curative-resection-of-stage-ii-colorectal-cancer
#8
Zhong Ye, Chun Wang, Limin Guo, Juan P Palazzo, Zhixing Han, Yinzhi Lai, Jing Jiang, James A Posey, Atrayee Basu Mallick, Bingshan Li, Li Jiang, Hushan Yang
Background: Use of chemotherapy in stage II colorectal cancer (CRC) is controversial because it improves survival only in some patients. We aimed to develop a statistical model using routine and readily available blood tests to predict the prognosis of patients with stage II CRC and to identify which patients are likely to benefit from chemotherapy. Methods: We divided 422 patients with stage II CRC into a training and a testing set. The association of routine laboratory variables and disease-free survival (DFS) was analyzed...
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30323087/nccn-guidelines-insights-small-cell-lung-cancer-version-2-2018
#9
Gregory P Kalemkerian, Billy W Loo, Wallace Akerley, Albert Attia, Michael Bassetti, Yanis Boumber, Roy Decker, M Chris Dobelbower, Afshin Dowlati, Robert J Downey, Charles Florsheim, Apar Kishor P Ganti, John C Grecula, Matthew A Gubens, Christine L Hann, James A Hayman, Rebecca Suk Heist, Marianna Koczywas, Robert E Merritt, Nisha Mohindra, Julian Molina, Cesar A Moran, Daniel Morgensztern, Saraswati Pokharel, David C Portnoy, Deborah Rhodes, Chad Rusthoven, Rafael Santana-Davila, Charles C Williams, Karin G Hoffmann, Miranda Hughes
The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for SCLC regarding immunotherapy, systemic therapy, and radiation therapy. For the 2018 update, new sections were added on "Signs and Symptoms of SCLC" and "Principles of Pathologic Review."
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30323086/first-line-treatment-of-widely-metastatic-braf-mutated-salivary-duct-carcinoma-with-combined-braf-and-mek-inhibition
#10
Victor T G Lin, Lisle M Nabell, Sharon A Spencer, William R Carroll, Shuko Harada, Eddy S Yang
Salivary duct carcinoma (SDC) is a rare and aggressive malignancy for which limited data exist to guide treatment decisions. With the advent of advanced molecular testing and tumor genomic profiling, clinicians now have the ability to identify potential therapeutic targets in difficult-to-treat cancers such as SDC. This report presents a male patient with widely metastatic SDC found on targeted next-generation sequencing to have a BRAF p.V600E mutation. He experienced a prolonged and robust response to first-line systemic chemotherapy with dabrafenib and trametinib...
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30323085/shades-of-survivorship
#11
Elyse R Park, Jeffrey Peppercorn, Areej El-Jawahri
No abstract text is available yet for this article.
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30323084/one-size-fits-all-really
#12
Margaret Tempero
No abstract text is available yet for this article.
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181425/being-critical-of-critical-care-given-to-people-with-metastatic-cancer-get-palliative-care-involved
#13
Talha Mehmood, Thomas J Smith
No abstract text is available yet for this article.
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181424/resurrection-of-parp-inhibitors-in-breast-cancer
#14
REVIEW
Tomas G Lyons, Mark E Robson
PARP enzymes are essential for DNA damage repair. Cancers with defective homologous recombination DNA repair, such has BRCA1 - and BRCA2 -mutated breast cancers, are targets for PARP inhibitors (PARPi) through the exploitation of synthetic lethality. A number of PARPi are currently undergoing clinical evaluation in breast cancer, with olaparib and talazoparib having demonstrated superior efficacy compared with standard chemotherapy in advanced germline BRCA -mutated cancer. This review describes the biological rationale for PARPi and presents the accumulating data on PARPi use in breast cancer...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181423/management-of-primary-ovarian-insufficiency-symptoms-in-survivors-of-childhood-and-adolescent-cancer
#15
REVIEW
Emma Gargus, Rebecca Deans, Antoinette Anazodo, Teresa K Woodruff
Cancer treatments can damage the ovaries, causing primary ovarian insufficiency (POI), a condition associated with numerous sequelae that impact long-term quality of life. This article systematically reviews the literature on the prevalence, surveillance, and treatment of POI in survivors of pediatric and adolescent and young adult (AYA) cancers. A systematic review of the literature was conducted in January 2018 through a search of Medline, Embase, Web of Science, and SCOPUS, alongside the screening of relevant reference lists...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181422/chronic-myeloid-leukemia-version-1-2019-nccn-clinical-practice-guidelines-in-oncology
#16
Jerald P Radich, Michael Deininger, Camille N Abboud, Jessica K Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M Kantarjian, Lori Maness, Leland Metheny, Joseph O Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg Purev, Michal G Rose, Neil P Shah, B Douglas Smith, David S Snyder, Kendra L Sweet, Moshe Talpaz, James Thompson, David T Yang, Kristina M Gregory, Hema Sundar
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient's age, ability to tolerate therapy, and the presence of comorbid conditions...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181421/chimeric-antigen-receptor-t-cell-therapy
#17
Ndiya Ogba, Nicole M Arwood, Nancy L Bartlett, Mara Bloom, Patrick Brown, Christine Brown, Elizabeth Lihua Budde, Robert Carlson, Stephanie Farnia, Terry J Fry, Morgan Garber, Rebecca A Gardner, Lauren Gurschick, Patricia Kropf, Jeff J Reitan, Craig Sauter, Bijal Shah, Elizabeth J Shpall, Steven T Rosen
Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181420/impact-of-nonconcordance-with-nccn-guidelines-on-resource-utilization-cost-and-mortality-in-de-novo-metastatic-breast-cancer
#18
Gabrielle B Rocque, Courtney P Williams, Bradford E Jackson, Stacey A Ingram, Karian I Halilova, Maria Pisu, Kelly M Kenzik, Andres Azuero, Andres Forero, Smita Bhatia
Background: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) have directed the care of patients with cancer for >20 years. Payers are implementing guideline-based pathway programs that restrict reimbursement for non-guideline-based care to control costs, yet evidence regarding impact of guidelines on outcomes, including mortality, Medicare costs, and healthcare utilization, is limited. Patients and Methods: This analysis evaluated concordance of first treatment with NCCN Guidelines for women with de novo stage IV metastatic breast cancer (MBC) included within the SEER-Medicare linked database and diagnosed between 2007 and 2013...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181419/benchmarking-cancer-centers-from-care-pathways-to-integrated-practice-units
#19
Anke Wind, Francisco Rocha Gonçalves, Edit Marosi, Lucia da Pieve, Monica Groza, Marco Asioli, Marco Albini, Wim van Harten
Background: Structuring cancer care into pathways can reduce variability in clinical practice and improve patient outcomes. International benchmarking can help centers with regard to development, implementation, and evaluation. A further step in the development of multidisciplinary care is to organize care in integrated practice units (IPUs), encompassing the whole pathway and relevant organizational aspects. However, research on this topic is limited. This article describes the development and results of a benchmark tool for cancer care pathways and explores IPU development in cancer centers...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181418/ability-to-predict-new-onset-psychological-distress-using-routinely-collected-health-data-a-population-based-cohort-study-of-women-diagnosed-with-breast-cancer
#20
Ania Syrowatka, James A Hanley, Daniala L Weir, William G Dixon, Ari N Meguerditchian, Robyn Tamblyn
Objectives: The primary objective of this study was to identify the predictors of new-onset psychological distress available in routinely collected administrative health databases for women diagnosed with breast cancer. The secondary objective was to explore whether the predictors vary based on the period of cancer care. Methods: A population-based cohort study followed 16,495 female patients with newly diagnosed breast cancer who did not experience psychological distress during the 14 months before breast cancer surgery...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
journal
journal
40348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"